Study of Human Leukocyte Antigen (HLA) Polymorphisms in Patients With Rheumatoid Arthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-02-28

Study Completion Date

2010-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rheumatoid arthritis (RA), affects between 0.3% and 1.0% of the population, it can lead to progressive joint destruction and severe disability. To date, two RA genetic susceptibility factors have been identified: HLA-DRB1-SE (Shared epitope) and PTPN22 620W alleles. The predictive value of the alleles for diagnosis of RA was previously investigated in cohorts of caucasians patients with early unclassified arthritis that showed restrained association between RA and HLA-SE. Despite the contribution of HLA to the overall genetic risk has been estimated to range from 30% to 50%, it has never been studied in the French west-Indian population.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Rheumatoid Arthritis Rheumatoid Arthritis according to ACR criteria of diagnosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Collect of 10 ml of peripheric blood for DNA extraction

After signed written consent, all patients have a clinic exam in order to assess the presence of eligibility criteria (Patient with Rheumatoid Arthritis that fulfil the ACR criteria of diagnosis)

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Rheumatoid Arthritis French West-Indian Patients with Rheumatoid Arthritis

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of Rheumatoid Arthritis according to ACR criteria
* Come from French West Indies (At least 3 grandparents are African-Caribbean)
* Sign written informed consent

* Blood donor
* Sign written informed consent
* Patient with no Rheumatoid Arthritis according to ACR criteria
* Come from French West Indies (At least 3 grandparents are African-Caribbean)

Exclusion Criteria

* Minor
* Patient with no Rheumatoid Arthritis according to ACR criteria
* Patient does not agree for a genetic study

For the control

* Minor
* Patient does not agree for a genetic study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Service de Rhumathologie CHU de Fort-de-France

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Georges JEAN-BAPTISTE, Professor of medecine

Role: PRINCIPAL_INVESTIGATOR

CHU de Fort-de-France

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service de rhumatologie CHU de Fort-de-France

Fort-de-France, , Martinique

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Martinique

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

09/B/02

Identifier Type: -

Identifier Source: org_study_id